CompletedNCT00250367
Risperidone or placebo added to mood stabilizers for mania in bipolarity
About this title
A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.
Read the official source — NCT00250367This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
Medication studyAges 18–65
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 1997
- Recruitment status
- Completed
- Enrollment listed in the registry
- 151
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00250367
- Official title
Show the full official title
The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of risperidone for people with bipolarity.
Who is behind this study?
The study sponsor is Janssen Pharmaceutica N.V., Belgium.
Did this study involve medication?
Yes. The study involved medication, including risperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Asenapine added to lithium or valproate for mania in bipolar I